Advances against Aspergillosis
Author:
Steinbach WJ, Stevens DA, Denning DW, Moss RB
Date: 17 January 2007
Abstract:
No abstract. First paragraph: As contemporary medicine advances treatment of life-threatening diseases with the addition of newer, aggressive chemotherapeutic regimens and the frequent use of bone marrow and organ transplantation, the rising incidence of invasive aspergillosis has paralleled the marked increase in immunocompromised patients. The incidence of invasive mold infections following hematopoietic stem cell transplantation has tripled in some series, with Aspergillus species the most common pathogen. Unfortunately, the overall survival rate among patients treated with the historical standard of amphotericin B is dismal, and until recently there were only 2 antifungals with inherent activity against Aspergillus, amphotericin B deoxycholate and itraconazole.
Download the full article (Disclaimer)
This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.